Guangxi Novglobe Biotechnology Co., Ltd. (“Novglobe Biotech”) is a high-tech enterprise specializing in the research, development and production of innovative medical products based on nitric oxide (NO). As a core member of the Novlead Biotech group, Novglobe Biotech deeply integrates the group's world-leading gas therapy technologies, aiming to lead "China's smart manufacturing" for NO-based consumer medical products. Located in Fangchenggang, Guangxi Province, the company has a modern GMP production complex covering an area of ​​more than 2000 square meters, equipped with first-class domestic and foreign equipment, with an annual production capacity of 60 million RMB. Since its founding in 2023, Novglobe Biotech has invested more than RMB 13 million in technological transformation and capacity building, establishing a complete industrial chain covering active medical products and passive products in various forms, including gels and tablets. Currently, the company has successfully launched 10 Class II medical devices. The company's flagship product, "Reactor Microcontrolled Release Nitric Oxide Generation Device", is China's first portable medical nitric oxide generation equipment, filling a significant gap in the domestic market. Novglobe Biotech has not only established an extensive network of branches in domestic hospitals and pharmacies, but is also actively expanding its activities internationally through platforms such as TikTok and Amazon, as well as through OEM/ODM partnerships, providing high-quality medical solutions to the global market. Guangxi Novglobe Biotechnology Co., Ltd. (“Novglobe Biotech”) is a high-tech enterprise specializing in the R&D and production of innovative Nitric Oxide (NO) medical devices. As a key member of the Novlead Biotech Group, Novglobe Biotech deeply integrates the group's world-leading technology in gas therapy, dedicated to leading the "Intelligent Manufacturing in China" for NO consumer medical devices. Located in Fangchenggang, Guangxi, the company boasts a modern GMP production facility exceeding 2,000 square meters, equipped with top-tier domestic and international machinery, with an annual production capacity valued at 60 million RMB. Since its establishment in 2023, Novglobe Biotech has invested over 13 million RMB in technology transformation and capacity building, establishing a full industry chain layout that covers active medical devices and passive products in various forms, including gels and tablets. Currently, the company has successfully launched 10 Class II medical devices. Its flagship product, the "Micro-Controlled Release Reactor NO Generation Device," is the first medical-grade portable NO generation equipment approved in China, filling a significant gap in the domestic market. Novglobe Biotech has not only established deep channels within domestic hospitals and pharmacies but is also actively expanding internationally through platforms like TikTok and Amazon, as well as via OEM/ODM partnerships, providing high-quality health solutions to the global market.